Markets
Omeros Stock Plunges 17% After Earnings And Plans To Curb Its Free-Drug Program
Drug sales rose 26% from the second quarter, but non-cash valuation losses left Omeros with a reported loss.
Omeros (OMER) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
Drug sales rose 26% from the second quarter, but non-cash valuation losses left Omeros with a reported loss.
Earnings
Current patients will receive enough Yartemlea to finish treatment as the company pursues reimbursed access abroad.
Earnings
A $62.0 million non-cash valuation loss pushed reported results into the red, even as Omeros generated cash from operations.
SEC Filings
The award has four price hurdles topping out at $40.00, a $17.88 exercise price and a five-year term, the company said.